Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116


1, 25(OH)₂D₃ inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes.

Guo J, Ma Z, Ma Q, Wu Z, Fan P, Zhou X, Chen L, Zhou S, Goltzman D, Miao D, Wu E.

Curr Med Chem. 2013;20(33):4131-41.


Inactivation of p27kip1 promotes chemical hepatocarcinogenesis through enhancing inflammatory cytokine secretion and STAT3 signaling activation.

Guo J, Ma Q, Zhou X, Fan P, Shan T, Miao D.

J Cell Physiol. 2013 Oct;228(10):1967-76. doi: 10.1002/jcp.24357.


Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.

Subramaniam A, Shanmugam MK, Ong TH, Li F, Perumal E, Chen L, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP, Hui KM, Sethi G.

Br J Pharmacol. 2013 Oct;170(4):807-21. doi: 10.1111/bph.12302.


1,25(OH)2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21(WAFI/CIP1).

Huang J, Yang G, Huang Y, Kong W, Zhang S.

Mol Med Rep. 2016 Feb;13(2):1373-80. doi: 10.3892/mmr.2015.4676. Epub 2015 Dec 11.


Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1).

Zhao Y, Tang Q, Ni R, Huang X, Wang Y, Lu C, Shen A, Wang Y, Li C, Yuan Q, Chen H, Cheng C, He S.

Hum Pathol. 2013 Mar;44(3):365-73. doi: 10.1016/j.humpath.2012.03.030. Epub 2012 Sep 17.


Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.

Swamy N, Chen TC, Peleg S, Dhawan P, Christakos S, Stewart LV, Weigel NL, Mehta RG, Holick MF, Ray R.

Clin Cancer Res. 2004 Dec 1;10(23):8018-27.


25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis.

Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S.

Science. 1997 Sep 19;277(5333):1827-30.


VDR and CYP27B1 are expressed in C2C12 cells and regenerating skeletal muscle: potential role in suppression of myoblast proliferation.

Srikuea R, Zhang X, Park-Sarge OK, Esser KA.

Am J Physiol Cell Physiol. 2012 Aug 15;303(4):C396-405. doi: 10.1152/ajpcell.00014.2012. Epub 2012 May 30.


Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice.

Tangpricha V, Spina C, Yao M, Chen TC, Wolfe MM, Holick MF.

J Nutr. 2005 Oct;135(10):2350-4.


Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma.

Zhao J, Lin W, Cao Z, Liu L, Zhuang Q, Zhong X, Hong Z, Peng J.

Oncol Rep. 2013 Sep;30(3):1309-14. doi: 10.3892/or.2013.2585. Epub 2013 Jul 3.


Hepatocellular carcinoma cells express 25(OH)D-1α-hydroxylase and are able to convert 25(OH)D to 1α,25(OH)₂D, leading to the 25(OH)D-induced growth inhibition.

Chiang KC, Yen CL, Yeh CN, Hsu JT, Chen LW, Kuo SF, Wang SY, Sun CC, Kittaka A, Chen TC, Yeh TS, Hsu SY, Juang HH.

J Steroid Biochem Mol Biol. 2015 Nov;154:47-52. doi: 10.1016/j.jsbmb.2015.06.008. Epub 2015 Jul 10.


IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma.

Gu FM, Li QL, Gao Q, Jiang JH, Zhu K, Huang XY, Pan JF, Yan J, Hu JH, Wang Z, Dai Z, Fan J, Zhou J.

Mol Cancer. 2011 Dec 15;10:150. doi: 10.1186/1476-4598-10-150.


SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.

Hong SW, Jung KH, Lee HS, Choi MJ, Son MK, Zheng HM, Hong SS.

Cancer Sci. 2012 Nov;103(11):1929-37. doi: 10.1111/j.1349-7006.2012.02409.x. Epub 2012 Sep 25. Erratum in: Cancer Sci. 2013 Oct;104(10):1389.


Tumoral Vitamin D Synthesis by CYP27B1 1-α-Hydroxylase Delays Mammary Tumor Progression in the PyMT-MMTV Mouse Model and Its Action Involves NF-κB Modulation.

Li J, Luco AL, Ochietti B, Fadhil I, Camirand A, Reinhardt TA, St-Arnaud R, Muller W, Kremer R.

Endocrinology. 2016 Jun;157(6):2204-16. doi: 10.1210/en.2015-1824. Epub 2016 Apr 27.


GYY4137, a hydrogen sulfide (H₂S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway.

Lu S, Gao Y, Huang X, Wang X.

Int J Oncol. 2014 Apr;44(4):1259-67. doi: 10.3892/ijo.2014.2305. Epub 2014 Feb 14.


Excess 25-hydroxyvitamin D3 exacerbates tubulointerstitial injury in mice by modulating macrophage phenotype.

Kusunoki Y, Matsui I, Hamano T, Shimomura A, Mori D, Yonemoto S, Takabatake Y, Tsubakihara Y, St-Arnaud R, Isaka Y, Rakugi H.

Kidney Int. 2015 Nov;88(5):1013-29. doi: 10.1038/ki.2015.210. Epub 2015 Jul 15.


Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse.

Masuda S, Byford V, Arabian A, Sakai Y, Demay MB, St-Arnaud R, Jones G.

Endocrinology. 2005 Feb;146(2):825-34. Epub 2004 Oct 21.


Anti-proliferative activity of 25-hydroxyvitamin D3 in human prostate cells.

Munetsuna E, Kawanami R, Nishikawa M, Ikeda S, Nakabayashi S, Yasuda K, Ohta M, Kamakura M, Ikushiro S, Sakaki T.

Mol Cell Endocrinol. 2014 Feb 15;382(2):960-70. doi: 10.1016/j.mce.2013.11.014. Epub 2013 Nov 27.


20,23-dihydroxyvitamin D3, novel P450scc product, stimulates differentiation and inhibits proliferation and NF-kappaB activity in human keratinocytes.

Janjetovic Z, Tuckey RC, Nguyen MN, Thorpe EM Jr, Slominski AT.

J Cell Physiol. 2010 Apr;223(1):36-48. doi: 10.1002/jcp.21992.


Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.

Chow EC, Quach HP, Vieth R, Pang KS.

Am J Physiol Endocrinol Metab. 2013 May 1;304(9):E977-89. doi: 10.1152/ajpendo.00489.2012. Epub 2013 Mar 12.


Supplemental Content

Support Center